Chemotherapy-induced neuropathic pain

A major problem which limits the dose of chemotherapy that can be given to  treat cancer patients for their disease is the occurrence of chemotherapy-induced peripheral neuropathy. This often causes patients to experience numbness, tingling or burning sensations beginning in the extremities. Symptoms often progress to a painful disabling condition, causing significant loss of function and quality of life. There are few effective treatments for this chemotherapy-induced pain.

Animal tests conducted with TTX indicate that it may be effective in chemotherapy induced neuropathic pain. WEX has completed a phase 2 study for CINP in the USA and now has filed a phase 3 protocol for CINP with the U.S. Food and Drug Administration (FDA).